Diaceutics issued an RNS statement this morning setting out its exposure to Silicon Valley Bank (SVB), which went into receivership on Friday, 10 March and the mitigating actions the company is taking. However, HSBC has announced that it has acquired the UK arm of SVB (SVB UK) with immediate effect and the UK government has announced that customers of SVB UK will be able to access their deposits and banking services as normal from today. Consequently, it seems likely that the mitigating actions announced by Diaceutics will not be required, including the potential need for additional funding. Diaceutics had requested a temporary suspension of its share on AIM and this also seems likely to be short lived.
13 Mar 2023
Diaceutics - SVB Risk Management
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Diaceutics - SVB Risk Management
Diaceutics Plc (DXRX:LON) | 103 0 0.0% | Mkt Cap: 87.2m
- Published:
13 Mar 2023 -
Author:
Colin Smith -
Pages:
3
Diaceutics issued an RNS statement this morning setting out its exposure to Silicon Valley Bank (SVB), which went into receivership on Friday, 10 March and the mitigating actions the company is taking. However, HSBC has announced that it has acquired the UK arm of SVB (SVB UK) with immediate effect and the UK government has announced that customers of SVB UK will be able to access their deposits and banking services as normal from today. Consequently, it seems likely that the mitigating actions announced by Diaceutics will not be required, including the potential need for additional funding. Diaceutics had requested a temporary suspension of its share on AIM and this also seems likely to be short lived.